TG Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.About TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.
CEOMichael Sean Weiss
CEOMichael Sean Weiss
Employees338
Employees338
HeadquartersMorrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded1993
Founded1993
Employees338
Employees338
TGTX Key Statistics
Market cap4.83B
Market cap4.83B
Price-Earnings ratio11.10
Price-Earnings ratio11.10
Dividend yield—
Dividend yield—
Average volume1.41M
Average volume1.41M
High today$31.21
High today$31.21
Low today$30.34
Low today$30.34
Open price$30.76
Open price$30.76
Volume982.53K
Volume982.53K
52 Week high$46.48
52 Week high$46.48
52 Week low$25.28
52 Week low$25.28
Stock Snapshot
The current TG Therapeutics(TGTX) stock price is $30.37, with a market capitalization of 4.83B. The stock trades at a price-to-earnings (P/E) ratio of 11.10.
On 2025-12-09, TG Therapeutics(TGTX) stock traded between a low of $30.34 and a high of $31.21. Shares are currently priced at $30.37, which is +0.1% above the low and -2.7% below the high.
The TG Therapeutics(TGTX)'s current trading volume is 982.53K, compared to an average daily volume of 1.41M.
During the past year, TG Therapeutics(TGTX) stock moved between $25.28 at its lowest and $46.48 at its peak.
During the past year, TG Therapeutics(TGTX) stock moved between $25.28 at its lowest and $46.48 at its peak.
Analyst ratings
78%
of 9 ratingsBuy
77.8%
Hold
11.1%
Sell
11.1%
People also own
Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.